MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes
VALENCIA, Calif., June 27, 2014 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq:MNKD) today announced that theU.S. Food & Drug Administration (FDA) has approved AFREZZA® (insulin human) Inhalation […]